January 27th -RCT on REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
[1/27, 9:30 PM] Biswas Sir Hod: Please share the current RCT on it's efficacy [1/27, 9:55 PM] Chanku: https://www.nejm.org/doi/full/10.1056/NEJMoa2108163 [1/27, 9:56 PM] Chanku: P-Eligible patients in cohort 1 were 18 years of age or older and were not hospitalized. These patients had a confirmed local SARS-CoV-2–positive diagnostic test result no more than 72 hours before randomization, with the onset of any Covid-19 symptom, as determined by the investigator, occurring no more than 7 days before randomization. Randomization into the initial phase 3 portion of the trial was stratified according to country and the presence of risk factors for severe Covid-19. In the amended phase 3 portion of the trial, only patients with at least one risk factor for severe Covid-19 were eligible. The full list of inclusion and exclusion criteria is provided in the protocol, available at NEJM.org. All the patients were assessed at baseline for anti–SARS-CoV-2 antibodies — anti-spike (S1) IgA, anti-...
